BLOG

A Pre-Treatment Mass Spectrometry-Based Serum Proteomic Test is Able to Stratify Patients with Ovarian Cancer Receiving Adjuvant Chemotherapy According to Overall and Disease-Free Survival and Identify Patients Likely to Exhibit Chemo-Resistance

Authors Sabine Kasimir-Bauer, Dep. of Gynecol & Obstet., University of Essen, Essen, Germany Thomas Krivak, Allegheny Health Network, Pittsburgh, PA, USA Thomas Herzog, University of Cincinnati, Cincinnati, OH, USA Arni Steingrimsson, Biodesix, Inc.,...

SUBSCRIBE TO THE BLOG

 

Why proteomics?

We recognize that most people are already familiar with the promise of genomic testing. Proteomic testing, however, is less well understood. Take a look at our latest video on proteomics to learn more.

Patient Video: Victoria’s Story

Video: Victoria, stage 4 lung cancer patient, discusses the impact that liquid biopsy testing had on her treatment and outlook.

Blood test is ready for clinical decision making: ddPCR detection of EGFR and KRAS mutations in ctDNA and EML4-ALK in circulating RNA show high sensitivity, specificity and concordance

The wait for results for a targeted mutation profile of a patient’s tumor has now been reduced to 72 hours. Results from a simple blood test (no invasive surgery) can determine whether the patient is eligible for targeted therapies such as EGFR tyrosine kinase inhibitors (TKIs) or whether the tumor has developed a T790M resistant mutation for which a 3rd generation TKI may be more appropriate.

What To Do When I Am Diagnosed?

Focus on hope not doubt. I am over a 3 year stage IV lung cancer survivor and if I had listened to the odds I might not be here now.

VIEW OUR BLOGS

READ

HOME     CONTACT     TERMS & CONDITIONS     CAREERS     FAQ     SITE MAP     NEWS

Quality Assurance Seal

ORDER A TEST KIT

CLICK HERE